1
|
Rolko T, Rauks-Pärgmäe T, Aluoja A, Tõru I, Janno S. Reliability and validity of the Estonian version of the Clinical Institute of Withdrawal Assessment for Alcohol scale. Nord J Psychiatry 2024; 78:347-352. [PMID: 38436948 DOI: 10.1080/08039488.2024.2324061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Accepted: 02/08/2024] [Indexed: 03/05/2024]
Abstract
AIMS Our aim was to adapt the Clinical Institute of Withdrawal Assessment for Alcohol scale (CIWA-Ar) into Estonian and test its reliability and validity. METHODS A total of 72 patients with alcohol withdrawal syndrome participated in the study. In order to assess the interrater reliability, at first assessment the CIWA-Ar was simultaneously completed by two nurses. In order to assess the sensitivity of the CIWA-Ar to the changes in the severity of the withdrawal syndrome, as well as its correlations to several indices characterizing the subjects' current condition, the CIWA-Ar, the Clinical Global Impression Severity subscale (CGI-S), the visual analogue scales for the assessment of the general feeling of malaise, anxiety and depression were filled in and the vital signs were measured at inclusion, in 4 h and after the withdrawal syndrome had been resolved. RESULTS The intraclass correlation coefficient (ICC) for the Estonian version of the CIWA-Ar total score, used as an indicator of interrater reliability, was excellent. The CIWA-Ar had significant correlations with the psychiatrists' CGI-S ratings of the severity of the patient's condition at all assessment points. Significant correlations were also found between CIWA-Ar and patients' self-ratings, the highest correlations found with self-rated anxiety and general feeling of malaise. CIWA-Ar total score did not correlate with simultaneously measured heart rate, systolic and diastolic blood pressure at the first assessment. At the second assessment, heart rate had a significant correlation with the CIWA-Ar total score. CONCLUSION Our study provides confirmation that the CIWA-Ar tool is well applicable in the Estonian language and culture setting.
Collapse
Affiliation(s)
- Teelia Rolko
- Psychiatry Clinic, Tartu University Hospital, Tartu, Estonia
| | | | - Anu Aluoja
- Psychiatry Clinic, Tartu University Hospital, Tartu, Estonia
- Department of Psychiatry, Faculty of Medicine, University of Tartu, Tartu, Estonia
| | - Innar Tõru
- Psychiatry Clinic, Tartu University Hospital, Tartu, Estonia
- Department of Psychiatry, Faculty of Medicine, University of Tartu, Tartu, Estonia
| | - Sven Janno
- Psychiatry Clinic, Tartu University Hospital, Tartu, Estonia
- Department of Psychiatry, Faculty of Medicine, University of Tartu, Tartu, Estonia
| |
Collapse
|
2
|
Wang H, Liu L, Zhou X, Guan Y, Li Y, Chen P, Duan R, Yang W, Rong X, Wu C, Yang J, Yang M, Jia Y, Hu J, Zhu X, Peng Y. Efficacy and safety of short-term edaravone or nerve growth factor add-on therapy for alcohol-related brain damage: A multi-centre randomised control trial. Addiction 2024; 119:717-729. [PMID: 38049955 DOI: 10.1111/add.16398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Accepted: 10/24/2023] [Indexed: 12/06/2023]
Abstract
AIMS To measure the therapeutic effect of an anti-oxidant, edaravone (EDV), or neurotrophic treatment with nerve growth factor (NGF) as an add-on treatment for alcohol-related brain damage (ARBD). DESIGN Multi-centre, randomised, single-blinded, comparative clinical trial. SETTING AND PARTICIPANTS One hundred and twenty-two inpatients recruited from seven hospitals in different regions of China, all diagnosed with ARBD and aged 18 to 65 years old; among them, only two were female. INTERVENTION AND COMPARATOR Patients were randomly assigned to receive one of three treatments for 2 weeks: 40 patients, treatment as usual (TAU: a combination of intramuscular injections of thiamine, intravenous infusions of other B vitamins with vitamin C and oral medication with vitamin E per day); 40, EDV add-on treatment to TAU (intravenous infusion with 30 mg of EDV twice per day); and 42, NGF add-on treatment to TAU (intramuscular injection of 20 μg of NGF per day). The patients underwent follow-up for 24 weeks. MEASUREMENTS The primary outcome was the composite score of executive cognitive function in the 2nd week after treatment, which was measured as the mean of the Z scores of the assessments, including the digit symbol substitute test (DSST), digit span memory test-forward (DST-F), digit span memory test-reverse (DST-R) and space span memory test (SSMT). The secondary outcomes were the composite scores at later follow-ups, the score for each component of cognitive function, global cognitive function measured by the Montreal Cognitive Assessment (MoCA), craving for alcohol and the safety of the therapies. FINDINGS EDV add-on treatment improved the composite score of executive cognitive function better than TAU in the 2nd week (adjusted mean difference: 0.24, 95% confidence interval 0.06 to 0.41; P = 0.008), but NGF add-on treatment did not (adjusted mean difference: 0.07, 95% confidence interval -0.09 to 0.24; P = 0.502). During the follow-up to 24 weeks, EDV add-on treatment improved the composite score of executive cognitive function and DST-R score better than TAU (both P < 0.01). Craving for alcohol was relieved in all three groups. No severe adverse events were observed. CONCLUSION The short-term addition of edaravone to supplementary therapy treatment for alcohol-related brain damage (ARBD) improved executive cognitive function in patients with ARBD.
Collapse
Affiliation(s)
- Hongxuan Wang
- Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| | - Lei Liu
- Mental Health Centre, First Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Xuhui Zhou
- Hunan Provincial Brain Hospital, Changsha, China
| | - Yanzhong Guan
- Department of Physiology and Neurobiology, Mudanjiang Medical University, Mudanjiang, China
| | - Yanfei Li
- Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Peiyun Chen
- Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| | - Ranran Duan
- Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Weibian Yang
- Hongqi Hospital, Mudanjiang Medical University, Mudanjiang, China
| | - Xiaoming Rong
- Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| | - Chengji Wu
- First Affiliated Hospital of Jiamusi University, Jiamusi, China
| | - Jianzhong Yang
- Department of Psychiatry, Second Affiliated Hospital of Kunming Medical University, Kunming, China
| | - Mei Yang
- Addiction Medicine Department, Shenzhen Mental Health Center, Shenzhen Kangning Hospital, Shenzhen, China
| | - Yanjie Jia
- Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Jian Hu
- Mental Health Centre, First Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Xiaofeng Zhu
- Department of Physiology and Neurobiology, Mudanjiang Medical University, Mudanjiang, China
| | - Ying Peng
- Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| |
Collapse
|
3
|
To DC, Steel TL, Carey KA, Joyce CJ, Salisbury-Afshar EM, Edelson DP, Mayampurath A, Churpek MM, Afshar M. Alcohol Withdrawal Severity Measures for Identifying Patients Requiring High-Intensity Care. Crit Care Explor 2024; 6:e1066. [PMID: 38505174 PMCID: PMC10950191 DOI: 10.1097/cce.0000000000001066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/21/2024] Open
Abstract
OBJECTIVES Alcohol withdrawal syndrome (AWS) may progress to require high-intensity care. Approaches to identify hospitalized patients with AWS who received higher level of care have not been previously examined. This study aimed to examine the utility of Clinical Institute Withdrawal Assessment Alcohol Revised (CIWA-Ar) for alcohol scale scores and medication doses for alcohol withdrawal management in identifying patients who received high-intensity care. DESIGN A multicenter observational cohort study of hospitalized adults with alcohol withdrawal. SETTING University of Chicago Medical Center and University of Wisconsin Hospital. PATIENTS Inpatient encounters between November 2008 and February 2022 with a CIWA-Ar score greater than 0 and benzodiazepine or barbiturate administered within the first 24 hours. The primary composite outcome was patients who progressed to high-intensity care (intermediate care or ICU). INTERVENTIONS None. MAIN RESULTS Among the 8742 patients included in the study, 37.5% (n = 3280) progressed to high-intensity care. The odds ratio for the composite outcome increased above 1.0 when the CIWA-Ar score was 24. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) at this threshold were 0.12 (95% CI, 0.11-0.13), 0.95 (95% CI, 0.94-0.95), 0.58 (95% CI, 0.54-0.61), and 0.64 (95% CI, 0.63-0.65), respectively. The OR increased above 1.0 at a 24-hour lorazepam milligram equivalent dose cutoff of 15 mg. The sensitivity, specificity, PPV, and NPV at this threshold were 0.16 (95% CI, 0.14-0.17), 0.96 (95% CI, 0.95-0.96), 0.68 (95% CI, 0.65-0.72), and 0.65 (95% CI, 0.64-0.66), respectively. CONCLUSIONS Neither CIWA-Ar scores nor medication dose cutoff points were effective measures for identifying patients with alcohol withdrawal who received high-intensity care. Research studies for examining outcomes in patients who deteriorate with AWS will require better methods for cohort identification.
Collapse
Affiliation(s)
- Daniel C To
- Department of Medicine, University of Wisconsin-Madison, Madison, WI
| | - Tessa L Steel
- Department of Medicine, University of Washington, Seattle, WA
| | - Kyle A Carey
- Department of Medicine, University of Chicago, Chicago, IL
| | - Cara J Joyce
- Department of Public Health Sciences, Loyola University Chicago, Maywood, IL
| | | | - Dana P Edelson
- Department of Medicine, University of Chicago, Chicago, IL
| | - Anoop Mayampurath
- Department of Medicine, University of Wisconsin-Madison, Madison, WI
- Department of Bioinformatics and Medical Informatics, University of Wisconsin-Madison, Madison, WI
| | - Matthew M Churpek
- Department of Medicine, University of Wisconsin-Madison, Madison, WI
- Department of Bioinformatics and Medical Informatics, University of Wisconsin-Madison, Madison, WI
| | - Majid Afshar
- Department of Medicine, University of Wisconsin-Madison, Madison, WI
- Department of Bioinformatics and Medical Informatics, University of Wisconsin-Madison, Madison, WI
| |
Collapse
|
4
|
Fluyau D, Kailasam VK, Pierre CG. Beyond benzodiazepines: a meta-analysis and narrative synthesis of the efficacy and safety of alternative options for alcohol withdrawal syndrome management. Eur J Clin Pharmacol 2023; 79:1147-1157. [PMID: 37380897 DOI: 10.1007/s00228-023-03523-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Accepted: 06/08/2023] [Indexed: 06/30/2023]
Abstract
PURPOSE To compare the efficacy and safety of non-benzodiazepines (non-BZDs) to benzodiazepines (BZDs) in the treatment of alcohol withdrawal syndrome (AWS). METHODS For relevant literature, Google Scholar, PubMed, Embase, OVID MEDLINE, EBSCO, Cochrane Central Registry of Controlled Trials, Web of Science, and Scopus were searched. Randomized control trials (RCTs) were included, omitted were nonblinded trials, blinded trials that were not randomized, and open-label studies. The Effective Public Health Practice Project Quality Assessment was used to assess the trial's quality. A meta-analysis and a narrative synthesis were carried out. RESULTS Twenty non-BZDs and five BZDs were investigated in thirty RCTs. Meta-analysis favored gabapentin over chlordiazepoxide and lorazepam (d = 0.563, p < 0.001) and carbamazepine over oxazepam and lorazepam (d = 0.376, p = 0.029), for reducing Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) scale scores. Eleven non-BZDs fared better than BZDs for reducing CIWA-Ar, Total Severity Assessment, Selective Severity Assessment, Borg and Weinholdt, and Gross Rating Scale for Alcohol Withdrawal scores. Eight non-BZDs outmatched BZDs regarding autonomic, motor, awareness, and psychiatric symptoms. Sedation and fatigue were prevalent in BZDs, while seizures were prevalent in non-BZDs. CONCLUSION For AWS treatments, non-BZDs are superior to or equally effective as BZDs. Non-BZD adverse events warrant further investigation. Agents that inhibit gated ion channels are promising candidates. PROTOCOL REGISTRATION PROSPERO CRD42022384875.
Collapse
Affiliation(s)
- Dimy Fluyau
- Department of Psychiatry, University of Florida, 1600 SW Archer Rd, Gainesville, FL, 32610, USA.
| | | | | |
Collapse
|
5
|
Airagnes G, Valter R, Ducoutumany G, Vansteene C, Trabut JB, Gorwood P, Dubertret C, Matta J, Charles-Nelson A, Limosin F. Magnesium in the treatment of alcohol withdrawal syndrome: a multicenter randomized controlled trial. Alcohol Alcohol 2023; 58:329-335. [PMID: 37012631 DOI: 10.1093/alcalc/agad021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 03/11/2023] [Accepted: 03/13/2023] [Indexed: 04/05/2023] Open
Abstract
OBJECTIVE Alcohol withdrawal syndrome (AWS) is a frequent and potentially life-threatening condition experienced in alcohol use disorder. Since hypomagnesemia is involved in AWS's severity, we conducted a multicenter double-blind randomized placebo-controlled trial to examine the efficacy of oral magnesium supplementation as an adjuvant therapy of AWS. MATERIAL AND METHODS Inpatients were recruited in six different centers if they had a baseline score higher than eight on the Revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar). The experimental treatment was magnesium lactate dehydrate, administrated three times per day providing a total of 426.6 mg per day and up to 15 days. The primary endpoint was the significant between-group difference of the CIWA-Ar total score change from baseline to 3 days later. The treatment group and baseline score were introduced as covariables in an analysis of covariance. RESULTS A total of 98 inpatients were included {71.4% of men; mean age of 49.1 years [standard deviation (SD): 10.3]}. In the intention-to-treat population, the mean reduction of the CIWA-Ar score in the experimental group between baseline and 3 days later was 10.1 (SD: 5.2), whereas it was 9.2 (SD: 3.9) in the control group. The absolute difference of the adjusted mean in the experimental group compared with the control group was -0.69 (SD: 0.72), which did not correspond to a significant between-group difference (P = 0.34). Per-protocol analysis and sensitivity analyses also supported this result. Supplementary analyses found no significant difference regarding benzodiazepine consumption, magnesium blood concentration, and satisfaction to care. CONCLUSIONS The present study does not support the rationale of systematic oral magnesium supplementation in patients with AWS.
Collapse
Affiliation(s)
- Guillaume Airagnes
- Department of Psychiatry and Addictology, AP-HP, Centre-Université Paris Cité, 20 rue Leblanc, 75015 Paris, France
- Faculté de Santé, UFR de Médecine, Université Paris Cité, 15 Rue de l'École de Médecine, 75006 Paris, France
- INSERM UMS011, Population-based Epidemiological Cohorts, Hôpital Paul Brousse Bât. 15/16, 16 avenue Paul Vaillant-Couturier, 94807 Villejuif Cedex, France
| | - Rémi Valter
- Department of Psychiatry and Addictology, AP-HP, Centre-Université Paris Cité, 20 rue Leblanc, 75015 Paris, France
| | - Géraldine Ducoutumany
- Department of Psychiatry and Addictology, AP-HP, Centre-Université Paris Cité, 20 rue Leblanc, 75015 Paris, France
| | - Clément Vansteene
- GHU Paris Psychiatrie et Neurosciences, CMME, Hôpital Sainte-Anne, 1 rue Cabanis, 75014 Paris, France
| | - Jean-Baptiste Trabut
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Hôpital Emile ROUX, Department of Addictology, 1 Avenue de Verdun, 94450 Limeil-Brévannes, France
| | - Philip Gorwood
- Faculté de Santé, UFR de Médecine, Université Paris Cité, 15 Rue de l'École de Médecine, 75006 Paris, France
- GHU Paris Psychiatrie et Neurosciences, CMME, Hôpital Sainte-Anne, 1 rue Cabanis, 75014 Paris, France
- Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, 1 rue Cabanis, 75014 Paris, France
| | - Caroline Dubertret
- Faculté de Santé, UFR de Médecine, Université Paris Cité, 15 Rue de l'École de Médecine, 75006 Paris, France
- Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, 1 rue Cabanis, 75014 Paris, France
- Department of Psychiatry and Addictology, AP-HP, Centre-Université Paris Cité, University Hospital Louis Mourier, 178 Rue des Renouillers, 92700 Colombes, France
| | - Joane Matta
- INSERM UMS011, Population-based Epidemiological Cohorts, Hôpital Paul Brousse Bât. 15/16, 16 avenue Paul Vaillant-Couturier, 94807 Villejuif Cedex, France
| | - Anais Charles-Nelson
- INSERM, Centre d'Investigation Clinique 1418 Épidémiologie Clinique, AP-HP, Hôpital Européen Georges-Pompidou, Unité de Recherche Clinique, 20 rue Leblanc, 75015 Paris, France
| | - Frédéric Limosin
- Department of Psychiatry and Addictology, AP-HP, Centre-Université Paris Cité, 20 rue Leblanc, 75015 Paris, France
- Faculté de Santé, UFR de Médecine, Université Paris Cité, 15 Rue de l'École de Médecine, 75006 Paris, France
- Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, 1 rue Cabanis, 75014 Paris, France
| |
Collapse
|
6
|
Al-Maqbali JS, Al Alawi AM, Al-Mamari Q, Al-Huraizi A, Al-Maqrashi N. Symptoms-triggered approach versus fixed-scheduled approach of benzodiazepines for management of alcohol withdrawal syndrome: Non-randomized controlled trial. Alcohol 2023; 106:10-14. [PMID: 36240945 DOI: 10.1016/j.alcohol.2022.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 09/29/2022] [Accepted: 09/29/2022] [Indexed: 01/25/2023]
Abstract
BACKGROUND Alcohol withdrawal syndrome, if untreated, can lead to potentially life-threatening complications. Benzodiazepines are the drugs of choice for the treatment of alcohol withdrawal syndrome. We aimed to compare the symptoms-triggered approach and fixed-dose approach of benzodiazepine administration for treatment of alcohol withdrawal syndrome in regard to the health care utilization measured by the total dose of benzodiazepines, length of hospital stays, and 90-day readmissions rate. METHODS A single-center prospective non-randomized controlled trial included all patients diagnosed with alcohol withdrawal syndrome. The group of patients admitted between October 1, 2019, and September 30, 2020, were treated with the fixed-scheduled approach (n = 150), while all patients admitted between November 1, 2020, to October 31, 2021, were treated with the symptoms-trigger approach (n = 50). RESULTS The fixed-dose approach group showed a significant higher 90-day readmissions rate (HR: 2.61; 95% CI = 1.18, 6.84; p = 0.01). Kaplan-Meier survival analysis showed a significantly shorter duration to the first readmission in the fixed-scheduled approach group (HR: 2.3; 95% CI = 5.6, 1.16; p = 0.02). The symptoms-triggered approach group required a significantly lower dose of diazepam (40 mg vs. 10 mg; p < 0.01) and a higher dose of thiamine (800 mg vs. 600 mg; p < 0.01). Length of hospital stay was significantly increased in the symptoms-triggered approach group (3.9 vs. 2.2 days; p < 0.01). DISCUSSION The use of a symptoms-triggered approach to treat alcohol withdrawal syndrome was associated with a lower 90-day readmission rate, prolonged period to the first readmission, and reduced total dose of benzodiazepines, but longer length of hospital stays. CONCLUSION The symptoms-triggered approach is safe, cost-effective, and associated with reduced alcohol dependence relapse.
Collapse
Affiliation(s)
| | - Abdullah M Al Alawi
- Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman; Internal Medicine Training Program, Oman Medical Specialty Board, Muscat, Oman.
| | - Qasim Al-Mamari
- Department of Nursing, Sultan Qaboos University Hospital, Muscat, Oman
| | - Aisha Al-Huraizi
- Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman
| | - Nasiba Al-Maqrashi
- Internal Medicine Training Program, Oman Medical Specialty Board, Muscat, Oman
| |
Collapse
|
7
|
Gallus S, Lugo A, Borroni E, Vignoli T, Lungaro L, Caio G, De Giorgio R, Zoli G, Caputo F. Symptoms of Protracted Alcohol Withdrawal in Patients with Alcohol Use Disorder: A Comprehensive Systematic Review. Curr Neuropharmacol 2023; 21:409-416. [PMID: 35794766 PMCID: PMC10190151 DOI: 10.2174/1570159x20666220706105253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 03/31/2022] [Accepted: 04/29/2022] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Alcohol withdrawal syndrome (AWS) is characterized by different phases (acute, early and protracted). Protracted alcohol withdrawal (PAW) presents some symptoms, which may persist for several weeks, months or even years after drinking cessation. METHODS We conducted a systematic review of the literature in major scientific databases on selected AWS symptoms (craving, sleep disorders, and anhedonia) in patients with alcohol use disorder. RESULTS Of the 102 eligible publications (70 RCTs and 32 cohort studies), 88 provided data on craving, 21 on sleep disorders, and 1 on anhedonia. Overall, 37 studies assessed craving using the Obsessive Compulsive Drinking Scale (OCDS). Pooled OCDS decreased from 24.2 at baseline to 18.8 at 1 week, 10.3 at 1 month and 9.7 at 3 months. The corresponding estimates for treated individuals were 23.9, 18.8, 8.7, and 8.8, and for non-treated subjects, they were 25.3, 13.9, 13.2, and 11.4, respectively. In 4 studies assessing sleep disorders using the Epworth Sleeping Scale (ESS), the scale remained stable in time, i.e., 7.3 at baseline, 7.3 at 1 week, 7.2 at 1 month, and 7.1 at 3 months. CONCLUSION This study confirms the presence of PAW after the resolution of the acute phase of AWS. The pharmacological approach to managing PAW may ensure a more rapid reduction of symptoms in three weeks. We highlight the importance of studying PAW and the ability of pharmacological treatment to reduce its symptoms. This review protocol is registered in Prospero (registration number: CRD42020211265). SUMMARY This systematic review summarizes literature on major symptoms of protracted alcohol withdrawal in patients with alcohol use disorder. The pharmacological approach to manage protracted alcohol withdrawal ensures a more rapid reduction of symptoms (craving in particular), achieving in three weeks similar results obtained only after almost 6 months without treatment.
Collapse
Affiliation(s)
- Silvano Gallus
- Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Alessandra Lugo
- Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Elisa Borroni
- Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Teo Vignoli
- Department of Addiction and Mental Health, Romagna Healthcare Service, Lugo Addiction Unit, Bologna, Emilia- Romagna, Italy
| | - Lisa Lungaro
- Department of Translational Medicine, Centre for the Study and Treatment of Alcohol-Related Diseases, University of Ferrara, Ferrara, Italy
| | - Giacomo Caio
- Department of Translational Medicine, Centre for the Study and Treatment of Alcohol-Related Diseases, University of Ferrara, Ferrara, Italy
| | - Roberto De Giorgio
- Department of Translational Medicine, Centre for the Study and Treatment of Alcohol-Related Diseases, University of Ferrara, Ferrara, Italy
| | - Giorgio Zoli
- Centre for the Study and Treatment of Alcohol-Related Diseases, Department of Translational Medicine, University of Ferrara, Ferrara, Italy
- Department of Internal Medicine, SS Annunziata Hospital, University of Ferrara, Cento (Ferrara), Italy
| | - Fabio Caputo
- Department of Translational Medicine, Centre for the Study and Treatment of Alcohol-Related Diseases, University of Ferrara, Ferrara, Italy
- Department of Internal Medicine, SS Annunziata Hospital, University of Ferrara, Cento (Ferrara), Italy
| |
Collapse
|
8
|
Abstract
Alcohol withdrawal arises in result of long-lasting or short, but massive, alcohol abuse, manifests itself with oppressive symptoms and in some cases is complicated by seizures, hallucinosis and delirium tremens that may be life-threatening for patients. The leading neurochemical factors underlying alcohol withdrawal syndrome and its complications are lack of GABA and excessive glutamate activity, which is important for therapy choice. The first-line drugs in the treatment of alcohol withdrawal syndrome and alcoholic delirium are benzodiazepines, which have the maximum pharmacological similarity with ethanol. Other medications, including barbiturates, anticonvulsants, propofol, dexmedetomidine, and antipsychotics, may be used as alternatives to and in addition to benzodiazepines, especially in the case of protracted delirium with therapeutic resistance. Certain prospects in the treatment of alcohol withdrawal syndrome are associated with ethylmethylhydroxypyridine succinate, which is a bit similar to benzodiazepines in its pharmacology.
Collapse
Affiliation(s)
- Y P Sivolap
- Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| |
Collapse
|